Clinical Trial Update: EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 1]

View source ↗

Summary

Phase 1 trial of EMD 1201081 plus 5-FU, cisplatin, and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)
• EMD 1201081

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: TERMINATED